Patents Assigned to Universität Zürich
  • Patent number: 11851484
    Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: December 26, 2023
    Assignee: UNIVERSITÄT ZÜRICH
    Inventors: Natalia Arenas-Ramirez, Iwan Beuvink, Onur Boyman, Barbara Brannetti, Andreas Katopodis, Simone Popp, Catherine Regnier, Chao Zou
  • Patent number: 11853875
    Abstract: A processor-implemented neural network method includes acquiring connection weight of an analog neural network (ANN) node of a pre-trained ANN; and determining, a firing rate of a spiking neural network (SNN) node of an SNN, corresponding to the ANN node, based on an activation of the ANN node which is determined based on the connection weight. and the firing rate is also determined based on information indicating a timing at which the SNN node initially fires.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: December 26, 2023
    Assignees: Samsung Electronics Co., Ltd., UNIVERSITAET ZUERICH
    Inventors: Bodo Ruckauer, Shih-Chii Liu
  • Patent number: 11845947
    Abstract: The present invention provides an improved Helminthosporium turcicum-resistant plant, in particular a maize plant which comprises a polynucleotide with one or more resistance-conferring genes, for example on a truncated chromosome fragment from the accession Pepitilla, as well as a cell, a tissue, a part, grain and seeds thereof, an isolated polynucleotide which comprises one or more resistance-conferring genes against Helminthosporium turcicum, a vector, a transgenic plant cell and a transgenic plant containing this polynucleotide. Furthermore, the invention encompasses suitable markers and their use in introducing resistance or the transgene into a plant, as well as the identification of improved maize plants which comprise a truncated chromosome fragment.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: December 19, 2023
    Assignees: KWS SAAT SE & CO. KGAA, UNIVERSITÄT ZÜRICH
    Inventors: Milena Ouzunova, Daniela Scheuermann, Beat Keller, Simon Krattinger, Thomas Wicker, Gerhard Herren, Severine Hurni, Bettina Kessel, Thomas Presterl, Carsten Knaak
  • Patent number: 11827721
    Abstract: The present invention relates to the field of antibodies useful in therapy and diagnosis. It specifically discloses bioconjugates comprising one or more antibodies bound to functionalized, magnetic nanoparticles. These bioconjugates are useful in cancer therapy, particularly for removing circulating tumor cells. The invention further pertains to specific functionalized, magnetic nanoparticles and to the manufacturing of such bioconjugates and such functionalized, magnetic nanoparticles.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: November 28, 2023
    Assignee: Universität Zürich and ETH Zurich
    Inventors: Antoine Florent Herzog, Wendelin Jan Stark, Martin Zeltner, Beatrice Beck-Schimmer, Anja Zabel
  • Patent number: 11807676
    Abstract: The invention relates to MHC-Ia open conformers as immunomodulatory agents, particularly in the treatment or prevention of cancer. The open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-heavy chain from the MHC-Ia molecules. The open conformer further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the MHC-Ia open conformers and immune checkpoint inhibitors. Furthermore, the invention relates to the use of MHC-Ia open conformers as immunomodulators, particularly in diseases where the interaction to diverse immunoregulatory receptors such as KIR3DL1, KIR3DL2, KIR3DL3, LILRB1, LILRB2, and PTPRJ modulates an immune response, and in diseases were the negative modulation of Tregs is a therapeutic strategy, e.g. infectious diseases.
    Type: Grant
    Filed: March 7, 2022
    Date of Patent: November 7, 2023
    Assignees: UNIVERSITÄT ZÜRICH, UNIVERSITÄT BASEL
    Inventors: Osiris Marroquin Belaunzaran, Christoph Renner
  • Publication number: 20230303680
    Abstract: The invention provides a human IL-2 (hlL-2)-specific monoclonal antibody, wherein a complex of hlL-2 and the monoclonal induces IL-2 signalling preferentially via CD25 and the trimeric IL-2R. The invention further provides a pharmaceutical composition comprising hlL-2 and said hlL-2-mAb for use treating inflammatory disease.
    Type: Application
    Filed: August 18, 2021
    Publication date: September 28, 2023
    Applicant: UNIVERSITÄT ZÜRICH
    Inventors: Onur BOYMAN, Ufuk KARAKUS, Miro RAEBER, Roman MELEDIN, Robert MAKA
  • Publication number: 20230295234
    Abstract: The present invention is directed to peptidomimetics having antibacterial activity, especially against Gram-negative bacteria. The peptidomimetics of the invention are compounds of the general formula (I), [X3]t—[X2]S—X1—P1—P2—P3—P4—P5—P6—P7—P8—P9—P10—P11—P12—P13—P14—P15—P16 and pharmaceutically acceptable salts thereof, as described in the description and in the claims. The invention is also directed to therapeutic uses of the peptidomimetics for the treatment or prevention of bacterial infections and diseases related to bacterial infections and to non-therapeutic uses of the peptidomimetics for preserving or disinfecting foodstuffs, cosmetics, medicaments or other nutrient-containing materials. In addition, the present invention provides an efficient synthetic process by which these compounds can, if desired, be made in parallel library-format. Moreover, the peptidomimetics of the invention show improved antimicrobial activity, low or no hemolysis of red blood cells and reduced cytotoxicity.
    Type: Application
    Filed: August 5, 2021
    Publication date: September 21, 2023
    Applicants: SPEXIS AG, UNIVERSITÄT ZÜRICH
    Inventors: Daniel OBRECHT, Anatol LUTHER, Grégory UPERT, Nicolas DESJONQUERES, Emile BRABET, Peter ZBINDEN, Oliver ZERBE, Kerstin MÖHLE
  • Patent number: 11733329
    Abstract: A magnetic resonance (MR) apparatus comprises magnet means for generating a main magnetic field in a sample region, encoding means for generating encoding magnetic fields superimposed to the main magnetic field, RF transmitter means for generating MR radiofrequency fields, driver means for operating said encoding means and RF transmitter means to generate superimposed time dependent encoding fields and radiofrequency fields according to an MR sequence for forming images or spectra; and acquisition means for acquiring an MR signal from said object. The magnet means comprise a primary magnetic field source providing a static magnetic field B0 and at least one secondary magnetic field source providing an adjustable magnetic field B?.
    Type: Grant
    Filed: August 1, 2021
    Date of Patent: August 22, 2023
    Assignees: UNIVERSITAET ZUERICH, ETH ZURICH
    Inventors: David Brunner, Simon Gross, Klaas Pruessmann
  • Publication number: 20230220416
    Abstract: The present invention relates to a method for transducing a target cell, the method comprising the step of contacting a target cell with a retroviral vector and a compound capable of enhancing transduction efficiency or a combination of such compounds, wherein the target cell is pre- and/or co-stimulated by pre- and/or co-incubation with said transduction enhancing compound or a combination of transduction enhancing compounds prior to and/or during contacting the target cell with the retroviral vector.
    Type: Application
    Filed: April 7, 2021
    Publication date: July 13, 2023
    Applicant: Universität Zürich
    Inventors: Oleksandr PASTUKHOV, Ulrich SILER, Janine REICHENBACH
  • Publication number: 20230212126
    Abstract: The present invention relates to small-molecule inhibitors of the FRS2-FGFR interaction. The present invention relates the small-molecule inhibitors for use as a medicament and for use in cancer or metastasis treatment or prevention.
    Type: Application
    Filed: June 8, 2021
    Publication date: July 6, 2023
    Applicants: UNIVERSITÄT ZÜRICH, ETH ZÜRICH
    Inventors: Gisbert SCHNEIDER, Cyrill BRUNNER, Martin BAUMGARTNER, Karthiga Santhana KUMAR, Oliver ZERBE
  • Publication number: 20230212340
    Abstract: The present invention relates to a contrast agent suitable for ex vivo imaging, particularly of vascular structures and renal tubular structures, and a method for ex vivo imaging. The contrast agent is a polymer comprising monomers M. The monomer comprises a backbone having 2 to 6 elements, wherein at least one element is —CH(R)— or —N(R)—. R is a moiety -E-H, -L-(NH2)m or a moiety of formula 1, with E, L, R1 and R2 being defined as described in the present specification. The monomer comprises at least one —I to allow detection via X-ray and at least one —NH2 to allow crosslinking. Furthermore, the monomer comprises polar functional groups that contribute to water solubility. To avoid extravasation and glomerular filtration, the polymers are pre-crosslinked before the vasculature of a tissue, an organ or whole animal is perfused. After perfusion, the pre-crosslinked contrast agent is further crosslinked to be retained within the tissue, organ or animal permanently.
    Type: Application
    Filed: December 4, 2020
    Publication date: July 6, 2023
    Applicant: UNIVERSITÄT ZÜRICH
    Inventors: Bernhard SPINGLER, Ngoc An LE, Vartan KURTCUOGLU, Willy KUO
  • Publication number: 20230212124
    Abstract: The present invention relates to small-molecule inhibitors of the FRS2-FGFR interaction. The present invention relates the small-molecule inhibitors for use as a medicament and for use in cancer treatment or prevention.
    Type: Application
    Filed: June 8, 2021
    Publication date: July 6, 2023
    Applicants: UNIVERSITÄT ZÜRICH, ETH ZÜRICH
    Inventors: Gisbert SCHNEIDER, Cyrill BRUNNER, Martin BAUMGARTNER, Karthiga Santhana KUMAR, Oliver ZERBE
  • Patent number: 11684697
    Abstract: The present invention concerns a tissue-engineered medical device, as well as a method for the production said medical device, comprising the following steps: providing a polymer scaffold comprising a mesh comprising polyglycolic acid, and a coating comprising poly-4-hydroxybutyrate; application of a cell suspension containing preferably human cells to the polymer scaffold; placement of the seeded polymer scaffold in a bioreactor and mechanical stimulation by exposure to a pulsatile flux of incremental intensity, thereby forming an extracellular matrix; mounting of the graft on a conduit stabilizer and incubation in cell culture medium; decellularisation of the graft in a washing solution; nuclease treatment of the graft; and rinsing of graft. The invention further comprises and various steps of quality control of the tissue-engineered medical device.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: June 27, 2023
    Assignee: UNIVERSITÄT ZÜRICH
    Inventors: Simon-Philipp Hoerstrup, Maximilian Y. Emmert, Frank Baaijens, Anita Driessen-Mol
  • Patent number: 11680085
    Abstract: The present invention relates to a cyclic peptide, a conjugate comprising said cyclic peptide and a lipopeptide building block, a bundle of said conjugates, a synthetic virus-like particle comprising at least one bundle of conjugates and pharmaceutical compositions comprising the same. The present invention further relates to said cyclic peptide, said conjugate said bundle of conjugates, said synthetic virus-like particle and said pharmaceutical compositions for use as a medicament, preferably for use in a method for preventing of an infectious disease or reducing the risk of an infectious disease, more preferably for use in a method for preventing or reducing the risk of an infectious disease associated with or caused by a respiratory syncytial virus.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: June 20, 2023
    Assignees: VIROMETIX AG, UNIVERSITÄT ZÜRICH
    Inventors: Arin Ghasparian, Armando Zuniga, Aniebrys Marrero Nodarse, Oliver Rassek, John A. Robinson, Kerstin Möhle
  • Patent number: 11661676
    Abstract: The invention relates to a method for selecting a sequence set from a library of expressed nucleic acid sequences, wherein cells are provided, each cell comprises an expressed nucleic acid sequence expressed as a target protein. The cells are encapsulated by treating them with a cationic polysaccharide and subsequently treating them with an anionic polysaccharide, yielding encapsulated cells, perforating the membrane of the encapsulated cells, yielding solubilized compartments, contacting them with a ligand to said target protein, the ligand bearing a detectable label, and selecting a subset of solubilized compartments as a function of detectable label and isolating the expressed nucleic acid sequences from the selection as a selected sequence set.
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: May 30, 2023
    Assignee: UNIVERSITÄT ZÜRICH
    Inventors: Daniel Scott, Andreas Plückthun
  • Publication number: 20230151118
    Abstract: The present invention relates to a non-agonist ligand of ARTC1, which inhibits the ADP-ribosyltransferase activity of ARTC1, or an inhibitor nucleic acid sequence capable of downregulating or inhibiting expression of a target nucleic acid sequence encoding ARTC1, for use in prevention or treatment of cancer. The invention also relates to a method for diagnosis of cancer.
    Type: Application
    Filed: April 6, 2021
    Publication date: May 18, 2023
    Applicants: UNIVERSITÄT ZÜRICH, UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF
    Inventors: Friedrich NOLTE, Stephan MENZEL, Tobias SUTER, Michael HOTTIGER, Denise DORVIGNIT-PEDROSO, Jesus GLAUS-GARZON, Kathrin NOWAK, Fabio AIMI
  • Publication number: 20230139165
    Abstract: The present invention relates to an immersion microscope objective (10) for inspecting a sample (S) in an immersion medium (M), comprising: at least one concave minor (3), at least one optical element (1) comprising an aspherical surface (2) facing the at least one concave minor (3), and an internal space (4) arranged between the at least one concave minor (3) and said aspherical surface (2), said internal space (4) being configured to be filled with an immersion medium (M) such that the immersion medium (M) contacts the at least one concave minor (3) and the aspherical surface (2). According to the present invention, the aspherical interface (2) is shaped such that the working distance (7) of the immersion microscope objective (10) varies by less than 1% when the refractive index n of said immersion medium (M) is increased or decreased by at least 0.025.
    Type: Application
    Filed: April 12, 2021
    Publication date: May 4, 2023
    Applicant: UNIVERSITÄT ZÜRICH
    Inventors: Fabian Friedrich VOIGT, Fritjof HELMCHEN
  • Publication number: 20230116496
    Abstract: A modular artificial neural sensing system includes a hierarchical network of neural sensing units including a neuromimetic sensor array of artificial sensory synapses and sensory neurons for receiving physicochemical sensed signals and for outputting sensor output signals. An artificial neural network processor is adapted for processing the sensor output signals and includes processor neurons interconnected by processor synapses forming first connections and second connections. The processor outputs processor output signals. A first sensor interface feeds processed or unprocessed sensed signals into the processor. A second sensor interface receives output predicted signals from other neural sensing units and feeds processed or unprocessed output predicted signals into the processor. A signal decoder decodes the processor output signals and outputs decoder output signals.
    Type: Application
    Filed: January 21, 2021
    Publication date: April 13, 2023
    Applicants: UNIVERSITÄT ZÜRICH, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS
    Inventors: Josep Maria MARGARIT TAULÉ, Shih-Chii LIU, Cecilia JIMÉNEZ JORQUERA
  • Publication number: 20230107228
    Abstract: A computer-implemented method is used to adapt a first artificial neural network for data classification tasks. The first artificial neural network is characterized by a first number of first weight parameters, and includes a set of first network layers. The method includes freezing at least some of the first weight parameters of the first neural network to obtain frozen first weight parameters and duplicating the frozen first weight parameters to obtain duplicated first weight parameters. A second artificial neural network is applied to the duplicated first weight parameters to obtain modulated first weight parameters. The second artificial neural network is characterized by a second number of second weight parameters, the second number being smaller than the first number. The frozen first weight parameters are replaced in the first neural network with the modulated first weight parameters to obtain a modulated first artificial neural network adapted for a data classification task.
    Type: Application
    Filed: October 5, 2022
    Publication date: April 6, 2023
    Applicant: UNIVERSITÄT ZÜRICH
    Inventors: Yuhuang HU, Shih-Chii LIU
  • Publication number: 20230106313
    Abstract: The invention provides a bacterial composition comprising, or consisting of, one or more of the genera of bacteria selected from Anaerostipes, and/or Roseburia, for treatment, or for prevention of recurrence, of cancer. In another aspect, the invention relates to a combination medicament for use in the treatment or the prevention of recurrence of cancer comprising a bacterial composition as specified herein and an antineoplastic treatment, particularly a combination medicament comprising a bacterial composition and a cancer chemotherapy drug, or a bacterial composition as provided herein and a cancer immunotherapy drug.
    Type: Application
    Filed: February 11, 2021
    Publication date: April 6, 2023
    Applicant: UNIVERSITÄT ZÜRICH
    Inventors: Michael SCHARL, Ana MONTALBAN-ARQUES, Lubor BORSIG